Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …

Background Intramuscular AZD7442 (tixagevimab–cilgavimab [Evusheld; AstraZeneca]) has
been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV …

Coronaviruses are important human and animal pathogens. At the end of 2019, a novel
coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in …

Immunocompromised patients, such as those with a haematological malignancy, are at
higher risk of SARS‐CoV‐2 infection, severe outcomes and mortality. Tixagevimab …

Some proportions of populations, such as immunocompromised patients and organ
transplant recipients might have inadequate immune responses to the vaccine for …

Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

Since the emergence of the Omicron variant of SARS-CoV-2, though considered less
virulent, hospitalization and death rates among immunocompromised patients remain high …

Abstract Background Coronavirus disease 2019 (COVID-19) is associated with increased
morbidity and mortality among immunocompromised patients. Tixagevimab–cilgavimab (Tix …

Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …